[HTML][HTML] Telomere maintenance mechanisms in cancer
T Bordeira Gaspar, A Sá, JM Lopes… - Genes, 2018 - mdpi.com
Tumour cells can adopt telomere maintenance mechanisms (TMMs) to avoid telomere
shortening, an inevitable process due to successive cell divisions. In most tumour cells …
shortening, an inevitable process due to successive cell divisions. In most tumour cells …
[HTML][HTML] Novel targeted therapies for metastatic thyroid cancer—a comprehensive review
M Al-Jundi, S Thakur, S Gubbi, J Klubo-Gwiezdzinska - Cancers, 2020 - mdpi.com
The knowledge on thyroid cancer biology has grown over the past decade. Thus, diagnostic
and therapeutic strategies to manage thyroid cancer are rapidly evolving. With new insights …
and therapeutic strategies to manage thyroid cancer are rapidly evolving. With new insights …
[HTML][HTML] Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy
Y Liu, J Wang, X Hu, Z Pan, T Xu, J Xu, L Jiang… - Drug Resistance …, 2023 - Elsevier
Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …
[HTML][HTML] Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy
J Liu, Y Liu, Y Lin, J Liang - Endocrinology and Metabolism, 2019 - ncbi.nlm.nih.gov
The retained functionality of the sodium iodide symporter (NIS) expressed in differentiated
thyroid cancer (DTC) cells allows the further utilization of post-surgical radioactive iodine …
thyroid cancer (DTC) cells allows the further utilization of post-surgical radioactive iodine …
TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease
M Melo, A Gaspar da Rocha, R Batista… - The Journal of …, 2017 - academic.oup.com
Context Little is known about the frequency of key mutations in thyroid cancer metastases
and its relationship with the primary tumor genotype. Objectives To evaluate the frequency of …
and its relationship with the primary tumor genotype. Objectives To evaluate the frequency of …
The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer
BRAF V600E and TERT promoter mutations, particularly their genetic duet, are well known
to be associated with poor clinical outcomes of papillary thyroid cancer (PTC). Loss of …
to be associated with poor clinical outcomes of papillary thyroid cancer (PTC). Loss of …
[HTML][HTML] Redifferentiation of radioiodine-refractory thyroid cancers
C Buffet, J Wassermann, F Hecht… - Endocrine-Related …, 2020 - erc.bioscientifica.com
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
[HTML][HTML] Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis
J Yang, Y Gong, S Yan, H Chen, S Qin, R Gong - Endocrine, 2020 - Springer
Background The association between telomerase reverse transcriptase (TERT) promoter
mutations and some clinical behaviors in thyroid cancer remains controversial and requires …
mutations and some clinical behaviors in thyroid cancer remains controversial and requires …
[HTML][HTML] Telomerase reverse transcriptase (TERT) regulation in thyroid cancer: a review
BA McKelvey, CB Umbricht, MA Zeiger - Frontiers in Endocrinology, 2020 - frontiersin.org
Telomerase reverse transcriptase (TERT) is the catalytic subunit of the enzyme telomerase
and is essential for telomerase activity. Upregulation of TERT expression and resulting …
and is essential for telomerase activity. Upregulation of TERT expression and resulting …
The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer
J Cao, X Zhu, Y Sun, X Li, C Yun, W Zhang - European Journal of Nuclear …, 2022 - Springer
Abstract Objective The BRAF V600E and TERT promoter mutations are well known to be
associated with poor clinical outcomes of papillary thyroid cancer (PTC). Radioactive iodide …
associated with poor clinical outcomes of papillary thyroid cancer (PTC). Radioactive iodide …